Most-Upgraded Stocks NASDAQ:ACAD ACADIA Pharmaceuticals - ACAD Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ACADIA Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $18.82 +0.12 (+0.64%) (As of 03/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$18.65▼$19.1050-Day Range$18.24▼$20.9252-Week Range$12.24▼$28.06Volume878,701 shsAverage Volume1.56 million shsMarket Capitalization$3.05 billionP/E RatioN/ADividend YieldN/APrice Target$21.44 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media ACADIA Pharmaceuticals MarketRank™ ForecastAnalyst RatingHold2.41 Rating ScoreUpside/Downside13.9% Upside$21.44 Price TargetShort InterestBearish5.31% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.28Based on 7 Articles This WeekInsider TradingSelling Shares$427,672 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.56) to ($0.05) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.11 out of 5 starsMedical Sector487th out of 1,004 stocksPharmaceutical Preparations Industry226th out of 489 stocks 3.2 Analyst's Opinion Consensus RatingACADIA Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.41, and is based on 9 buy ratings, 6 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $21.44, ACADIA Pharmaceuticals has a forecasted upside of 13.9% from its current price of $18.82.Amount of Analyst CoverageACADIA Pharmaceuticals has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.31% of the float of ACADIA Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverACADIA Pharmaceuticals has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in ACADIA Pharmaceuticals has recently increased by 5.72%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldACADIA Pharmaceuticals does not currently pay a dividend.Dividend GrowthACADIA Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACAD. Previous Next 2.9 News and Social Media Coverage News SentimentACADIA Pharmaceuticals has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for ACADIA Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest20 people have searched for ACAD on MarketBeat in the last 30 days. This is an increase of 11% compared to the previous 30 days.MarketBeat Follows9 people have added ACADIA Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ACADIA Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $427,672.00 in company stock.Percentage Held by Insiders28.40% of the stock of ACADIA Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions92.79% of the stock of ACADIA Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ACADIA Pharmaceuticals are expected to grow in the coming year, from ($0.56) to ($0.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ACADIA Pharmaceuticals is -14.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ACADIA Pharmaceuticals is -14.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioACADIA Pharmaceuticals has a P/B Ratio of 7.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About ACADIA Pharmaceuticals (NASDAQ:ACAD) StockACADIA Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.Read More Receive ACAD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ACAD Stock News HeadlinesMarch 29, 2023 | marketwatch.comParkinson Disease Drugs Market Application, Product, Sales and Forecast 2023-2031March 29, 2023 | markets.businessinsider.comSatsuma Pharmaceuticals (STSA) Gets a Hold from Mizuho SecuritiesApril 1, 2023 | Legacy Research (Affiliate) (Ad)Bear market expert makes new predictionNobody believed Larry Benedict's prediction in February 2020. The DOW plunged 3.5%, and he told CNBC, "It seems like there's much more to come." Within a month, the market plummeted 34%. Then, nobody believed Larry at the start of last year, either. He predicted that "all the indexes will be negative for the year," with the Nasdaq leading the way. Once again, he was spot-on.March 29, 2023 | marketwatch.comPsychedelic Medicine Market New Ready Report Analysis 2028March 29, 2023 | americanbankingnews.comBrokerages Set ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Price Target at $21.44March 28, 2023 | markets.businessinsider.comSVB Securities Reaffirms Their Buy Rating on ACADIA Pharmaceuticals (ACAD)March 25, 2023 | markets.businessinsider.comAmylyx Pharmaceuticals Inc (AMLX) Gets a Buy from CitigroupMarch 24, 2023 | marketwatch.comOral Dissolvable Films Market Insights and Forecast to 2031April 1, 2023 | Legacy Research (Affiliate) (Ad)Stocks are for suckers – try this insteadThis has nothing to do with dividends, day trading... taking out a loan... or anything like that. What you need is about 3 seconds to execute this simple financial maneuver...March 16, 2023 | msn.comBiotech Stock Roundup: ACAD's Drug Approval, SGEN to be Acquired by PFE & MoreMarch 15, 2023 | msn.comStrength Seen in Acadia (ACAD): Can Its 5.0% Jump Turn into More Strength?March 14, 2023 | msn.comCORRECTED-UPDATE 2-U.S. FDA approves Acadia's Rett syndrome drug (March 10)March 14, 2023 | reuters.comU.S. FDA approves Acadia's Rett syndrome drug (March 10)March 14, 2023 | markets.businessinsider.comAcadia Pharmaceuticals Gets Price Target Bumps By Analysts After FDA Approval Of Rett Syndrome DrugMarch 14, 2023 | marketwatch.comPsychedelic Medicine Market Analysis, Share by 2028March 14, 2023 | markets.businessinsider.comBank of America Securities Reaffirms Their Hold Rating on ACADIA Pharmaceuticals (ACAD)March 14, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on ACADIA Pharmaceuticals (ACAD)March 13, 2023 | msn.comCORRECTED-UPDATE 2-U.S. FDA approves Acadia's genetic Rett syndrome drug (March 10)March 13, 2023 | markets.businessinsider.comJMP Securities Keeps Their Buy Rating on ACADIA Pharmaceuticals (ACAD)March 13, 2023 | msn.comAcadia’s rare-disease drug to cost $575,000 to $595,000March 12, 2023 | msn.comGuess which ASX All Ords stock is rocketing 27% on a new FDA approvalMarch 11, 2023 | msn.comCORRECTED-UPDATE 1-U.S. FDA approves Acadia's genetic Rett syndrome drugMarch 10, 2023 | msn.comAcadia wins FDA nod for Rett syndrome therapyMarch 10, 2023 | finance.yahoo.comUPDATE 2-U.S. FDA approves Acadia's genetic Rett syndrome drugMarch 10, 2023 | finance.yahoo.comAcadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and OlderMarch 1, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD), DENTSPLY SIRONA (XRAY) and Privia Health Group (PRVA)February 28, 2023 | markets.businessinsider.comWhat 10 Analyst Ratings Have To Say About ACADIA PharmaceuticalsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ACAD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ACAD Company Calendar Last Earnings2/27/2023Today3/31/2023Next Earnings (Estimated)5/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ACAD CUSIPN/A CIK1070494 Webwww.acadia-pharm.com Phone(858) 558-2871Fax858-558-2872Employees514Year FoundedN/APrice Target and Rating Average Stock Price Forecast$21.44 High Stock Price Forecast$33.00 Low Stock Price Forecast$12.00 Forecasted Upside/Downside+13.9%Consensus RatingHold Rating Score (0-4)2.41 Research Coverage17 Analysts Profitability EPS (Most Recent Fiscal Year)($1.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-215,980,000.00 Net Margins-41.76% Pretax Margin-41.27% Return on Equity-50.65% Return on Assets-35.59% Debt Debt-to-Equity RatioN/A Current Ratio4.04 Quick Ratio3.99 Sales & Book Value Annual Sales$517.23 million Price / Sales5.90 Cash FlowN/A Price / Cash FlowN/A Book Value$2.47 per share Price / Book7.62Miscellaneous Outstanding Shares162,230,000Free Float116,157,000Market Cap$3.05 billion OptionableOptionable Beta0.59 Key ExecutivesStephen R. DavisChief Executive Officer & DirectorBrendan P. TeehanChief Operating Officer, EVP & Head-CommercialMark C. SchneyerChief Financial Officer & Executive Vice PresidentPonni SubbiahChief Medical Officer & Senior Vice PresidentSanjeev PathakSenior Vice President & Head-Clinical DevelopmentKey CompetitorsAmicus TherapeuticsNASDAQ:FOLDReata PharmaceuticalsNASDAQ:RETAZai LabNASDAQ:ZLABIVERIC bioNASDAQ:ISEECytokineticsNASDAQ:CYTKView All CompetitorsInsiders & InstitutionsRockefeller Capital Management L.P.Bought 4,811 shares on 3/6/2023Ownership: 0.286%Voya Investment Management LLCBought 5,765 shares on 2/28/2023Ownership: 0.149%Stephen DavisSold 3,851 sharesTotal: $72,321.78 ($18.78/share)Austin D KimSold 803 sharesTotal: $15,080.34 ($18.78/share)Brendan TeehanSold 461 sharesTotal: $8,657.58 ($18.78/share)View All Insider TransactionsView All Institutional Transactions ACAD Stock - Frequently Asked Questions Should I buy or sell ACADIA Pharmaceuticals stock right now? 17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last twelve months. There are currently 2 sell ratings, 6 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ACAD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACAD, but not buy additional shares or sell existing shares. View ACAD analyst ratings or view top-rated stocks. What is ACADIA Pharmaceuticals' stock price forecast for 2023? 17 analysts have issued twelve-month target prices for ACADIA Pharmaceuticals' stock. Their ACAD share price forecasts range from $12.00 to $33.00. On average, they expect the company's share price to reach $21.44 in the next twelve months. This suggests a possible upside of 13.9% from the stock's current price. View analysts price targets for ACAD or view top-rated stocks among Wall Street analysts. How have ACAD shares performed in 2023? ACADIA Pharmaceuticals' stock was trading at $15.92 at the beginning of 2023. Since then, ACAD stock has increased by 18.2% and is now trading at $18.82. View the best growth stocks for 2023 here. Are investors shorting ACADIA Pharmaceuticals? ACADIA Pharmaceuticals saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 8,500,000 shares, an increase of 5.7% from the February 28th total of 8,040,000 shares. Based on an average trading volume of 1,530,000 shares, the days-to-cover ratio is presently 5.6 days. Currently, 5.3% of the company's shares are short sold. View ACADIA Pharmaceuticals' Short Interest. When is ACADIA Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023. View our ACAD earnings forecast. How were ACADIA Pharmaceuticals' earnings last quarter? ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) issued its earnings results on Monday, February, 27th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.25) by $0.01. The biopharmaceutical company earned $136.49 million during the quarter, compared to the consensus estimate of $135.18 million. ACADIA Pharmaceuticals had a negative net margin of 41.76% and a negative trailing twelve-month return on equity of 50.65%. The firm's revenue was up 4.4% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.27) earnings per share. What ETFs hold ACADIA Pharmaceuticals' stock? ETFs with the largest weight of ACADIA Pharmaceuticals (NASDAQ:ACAD) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Psyk Etf (PSYK), First Trust NYSE Arca Biotechnology Index Fund (FBT), Invesco Dynamic Biotechnology & Genome ETF (PBE), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Products ETF (BBP), SPDR S&P Biotech ETF (XBI) and Principal Healthcare Innovators ETF (BTEC). What guidance has ACADIA Pharmaceuticals issued on next quarter's earnings? ACADIA Pharmaceuticals updated its FY 2023 earnings guidance on Monday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $520.00 million-$550.00 million, compared to the consensus revenue estimate of $569.16 million. What is Steve Davis' approval rating as ACADIA Pharmaceuticals' CEO? 8 employees have rated ACADIA Pharmaceuticals Chief Executive Officer Steve Davis on Glassdoor.com. Steve Davis has an approval rating of 88% among the company's employees. What other stocks do shareholders of ACADIA Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Pfizer (PFE), Tesla (TSLA), Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD) and Exelixis (EXEL). What is ACADIA Pharmaceuticals' stock symbol? ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD." Who are ACADIA Pharmaceuticals' major shareholders? ACADIA Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Price T Rowe Associates Inc. MD (2.64%), First Trust Advisors LP (1.78%), Morgan Stanley (1.70%), Geode Capital Management LLC (1.42%), JPMorgan Chase & Co. (1.29%) and Norges Bank (1.21%). Insiders that own company stock include Austin D Kim, Austin D Kim, Brendan Teehan, Elena Ridloff, James Kihara, James M Daly, Laura Brege, Mark C Schneyer, Michael J Yang, Srdjan R Stankovic, Srdjan R Stankovic and Stephen Davis. View institutional ownership trends. How do I buy shares of ACADIA Pharmaceuticals? Shares of ACAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ACADIA Pharmaceuticals' stock price today? One share of ACAD stock can currently be purchased for approximately $18.82. How much money does ACADIA Pharmaceuticals make? ACADIA Pharmaceuticals (NASDAQ:ACAD) has a market capitalization of $3.05 billion and generates $517.23 million in revenue each year. The biopharmaceutical company earns $-215,980,000.00 in net income (profit) each year or ($1.34) on an earnings per share basis. How many employees does ACADIA Pharmaceuticals have? The company employs 514 workers across the globe. How can I contact ACADIA Pharmaceuticals? ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The official website for the company is www.acadia-pharm.com. The biopharmaceutical company can be reached via phone at (858) 558-2871, via email at ir@acadia-pharm.com, or via fax at 858-558-2872. This page (NASDAQ:ACAD) was last updated on 4/1/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.